智通财经APP获悉，博安生物(06955)现跌超4%，截至发稿，跌4.17%，报17.25港元，成交额7130.16万港元。
消息面上，博安生物宣布，拟配售总计4800万股股份，占公告日期已发行股份总数约8.36%，配售价为每股16.42港元，较上一日收盘价折让约8.78%。此次配售预计募集资金净额约7.80亿港元，公司拟将50%主要用于研发、临床试验及产品制造；20%用于产品商业化以及30%用于补充营运资金和一般企业用途。值得注意的是，博安生物6月初宣布配售3840万股，净筹约3.96亿元。
值得注意的是，博安生物自主开发的靶向CD228创新抗体偶联药物(ADC)BA1302今年6月获得美国食品药品监督管理局(FDA)许可开展临床试验。BA1302拟用于治疗多种实体瘤，此前已获得FDA授予的鳞状非小细胞肺癌和胰腺癌的孤儿药资格认定，正在中国进行1期临床研究。公司将加快推进BA1302的全球开发进程，探索该药物在更多适应症中的临床应用价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.